Application of lycopene combined with L-carnitine in preparation of health food for preventing and / or delaying atherosclerosis

Abstract

The invention relates to application of lycopene combined with L-carnitine in preparation of health food for preventing and / or delaying atherosclerosis, and belongs to the technical field of food. The invention provides application of lycopene combined with L-carnitine in preparation of health food for preventing and / or delaying atherosclerosis. The lycopene and the L-carnitine show a synergistic effect in the process of reducing the ox-LDL content, and the combination of the lycopene and the L-carnitine can effectively improve the blood fat, serum inflammatory factor and serum adhesion factor levels of the body and improve the oxidation resistance of the body, so that the lycopene and the L-carnitine can be used for preventing and / or delaying the development of atherosclerosis.

Description

Technical Field

[0001] The invention relates to the technical field of food, and in particular to the application of lycopene combined with L-carnitine in the preparation of health food for preventing and / or delaying atherosclerosis. Background Art

[0002] Atherosclerosis is a common arteriosclerotic vascular disease, which is associated with increased levels of oxidized low-density lipoprotein (ox-LDL) in the body. Ox-LDL is one of the network intersections of oxidative stress and lipid metabolism disorders. It is derived from the oxidative modification of a large number of unsaturated fatty acids (such as arachidonic acid and linoleic acid) in LDL under oxidative stress conditions. Ox-LDL is cytotoxic and can induce the expression of adhesion factors on endothelial cells, macrophage proliferation, collagen deposition and platelet activation, and is closely related to the occurrence of atherosclerosis. Lycopene is a safe, non-toxic, natural, fat-soluble carotenoid. It is widely found in fruits and vegetables such as tomatoes, carrots, and watermelons. It is one of the strongest oxidants found in nature. Its antioxidant capacity is 100 times that of vitamin E and more than twice that of carotene. It is not only an exogenous antioxidant itself, but can also improve the status of enzymatic antioxidants such as superoxide dismutase (SOD) in cells, and can also increase the number of non-enzymatic antioxidants such as vitamin C and tocopherol. The absorption pattern in the human body is similar to that of dietary fat, and it has multiple physiological functions such as anti-oxidation, lipid-lowering, anti-cancer, immunity enhancement, cardiovascular and cerebrovascular protection, and skin protection. L-carnitine is an amino acid that promotes fat conversion, also known as vitamin BT. It is an indispensable nutrient for energy metabolism and has biological functions such as weight loss and lipid-lowering, anti-fatigue, and detoxification. Its sources mainly include exogenous intake and endogenous synthesis. Exogenous intake is supplemented by taking meat, animal offal, and eggs. The site of endogenous synthesis is mainly located in the liver and kidneys. The synthesis steps are to synthesize trimethyllysine with methionine and lysine as precursors, and then synthesize L-carnitine through multi-step enzymatic reactions. However, L-carnitine needs to be synergistic with choline, catechins, garcinia acid, and other components that can enhance basal metabolism and promote fat decomposition, transport, and oxidation in order to play a better role.

[0003] The research directions of existing technologies are mostly focused on the antioxidant effect of lycopene and the anti-obesity effect of L-carnitine. There are few studies on the related mechanisms and functions of the two in preventing and / or delaying atherosclerosis, and there are no reports on the prevention and / or delaying effects of lycopene combined with L-carnitine on atherosclerosis. Summary of the invention

[0004] The purpose of the present invention is to address the defects in the above-mentioned prior art and provide an application of lycopene combined with L-carnitine in the preparation of a health food for preventing and / or delaying atherosclerosis.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The present invention provides the use of lycopene combined with L-carnitine in the preparation of health food for preventing and / or delaying atherosclerosis.

[0007] Preferably, the mass ratio of lycopene to L-carnitine is 15-120:10-80.

[0008] The present invention also provides the use of lycopene combined with L-carnitine in the preparation of health food for reducing oxidized low-density lipoprotein.

[0009] Preferably, the mass ratio of lycopene to L-carnitine is 15-120:10-80.

[0010] The present invention also provides a health food, which comprises lycopene, L-carnitine and acceptable auxiliary materials.

[0011] Preferably, the mass ratio of lycopene to L-carnitine is 15-120:10-80.

[0012] The present invention also provides the use of the health food in preparing a preparation for preventing and / or delaying atherosclerosis.

[0013] The invention also provides application of the health food in preparing a preparation for reducing oxidized low-density lipoprotein.

[0014] The present invention has the following technical effects and advantages:

[0015] The lycopene and L-carnitine of the present invention show a synergistic effect in the process of reducing the ox-LDL content. The combined use of lycopene and L-carnitine can effectively improve the body's blood lipids, serum inflammatory factors and serum adhesion factor levels, and enhance the body's antioxidant capacity, thereby being used to prevent and / or delay the development of atherosclerosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 is the regression curve of lycopene on ox-LDL, in which the ordinate axis represents the reduction rate of ox-LDL, and the abscissa axis represents the logarithmic value of the final dose of lycopene;

[0017] Figure 2 is the regression curve of L-carnitine on ox-LDL, in which the ordinate axis represents the reduction rate of ox-LDL, and the abscissa axis represents the logarithmic value of the final dose of L-carnitine;

[0018] Figure 3 This is the regression curve of lycopene combined with L-carnitine on ox-LDL. The ordinate axis represents the reduction rate of ox-LDL, and the abscissa axis represents the logarithm of the sum of the final doses of lycopene and L-carnitine. DETAILED DESCRIPTION

[0019] The present invention provides the use of lycopene combined with L-carnitine in the preparation of health food for preventing and / or delaying atherosclerosis.

[0020] In the present invention, the mass ratio of lycopene to L-carnitine is 15-120:10-80, preferably 108:72.

[0021] The present invention also provides the use of lycopene combined with L-carnitine in the preparation of health food for reducing oxidized low-density lipoprotein.

[0022] In the present invention, the mass ratio of lycopene to L-carnitine is 15-120:10-80, preferably 108:72.

[0023] The present invention also provides a health food, which comprises lycopene, L-carnitine and acceptable auxiliary materials.

[0024] In the present invention, the mass ratio of lycopene to L-carnitine is 15-120:10-80, preferably 108:72.

[0025] The present invention also provides the use of the health food in preparing a preparation for preventing and / or delaying atherosclerosis.

[0026] The invention also provides application of the health food in preparing a preparation for reducing oxidized low-density lipoprotein.

[0027] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0028] Among the reagents of the present invention, lycopene and simvastatin were purchased from Shanghai Yuanye Biotechnology Co., Ltd., corn oil was purchased from COFCO Group Co., Ltd., and maintenance feed and high-fat feed were purchased from Beijing Keao Xieli Feed Co., Ltd.;

[0029] Among the instruments of the present invention, the DR-200BS ELISA analyzer was purchased from Wuxi Huawei Delang Instrument Co., Ltd., and the BS-420 fully automatic biochemical analyzer was purchased from Shenzhen Mindray Bio-Medical Electronics Co., Ltd.;

[0030] The test animals of the present invention were 4-week-old male SPF-grade ICR mice, weighing about 30 g, purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.

[0031] The test site of the present invention is the SPF animal room of China Agricultural University (Use License No.: SYXK (Beijing) 2015-0036);

[0032] The animal experiment of the present invention was approved by the Animal Ethics Committee of China Agricultural University, and the ethics approval number is AW52404202-4-1.

[0033] Example 1: Grouping and treatment of mice with lycopene or L-carnitine alone

[0034] 168 4-week-old male SPF ICR mice were selected and placed in an SPF animal room for group cage breeding. The ambient temperature was set at 26°C, the relative humidity was 50%, and the light duration was 12h / d. During this period, the corn cob bedding was changed once a week, drinking water was replenished regularly, and the SPF animal room was well ventilated. All mice were first fed with maintenance feed. After feeding for 7 days, all mice were divided into 14 groups, with 12 mice in each group, namely blank control group, corn oil control group, distilled water control group, positive control group, lycopene 1-5 groups, and L-carnitine 1-5 groups. The blank control group mice continued to be fed with maintenance feed, and the remaining 13 groups of mice were fed with high-fat feed; the nutritional components of maintenance feed and high-fat feed are shown in Table 1;

[0035] Table 1 Nutrient composition of mouse feed

[0036] Mouse feed Maintain feed High fat diet carbohydrate 59％ 43.3％ protein 21.1％ 15.5％ Cellulose 4.9％ 3.6％ Fat 4.2％ 3.1％ Ash 8％ 5.9％ phosphorus 1％ 0.7％ calcium 1.8％ 1.3％ sucrose —— 14.7％ lard —— 11.0％ cholesterol —— 0.9％ Sodium Cholate —— 0.1％ Casein —— Moderate Calcium bicarbonate —— Moderate Stone powder —— Moderate

[0037] Lycopene was dissolved in corn oil to prepare lycopene solutions with final concentrations of 2 mg / mL, 3 mg / mL, 5 mg / mL, 7.5 mg / mL and 12 mg / mL, respectively; L-carnitine was dissolved in distilled water to prepare L-carnitine solutions with final concentrations of 2 mg / mL, 4.5 mg / mL, 11 mg / mL, 26 mg / mL and 60 mg / mL, respectively; simvastatin was dissolved in corn oil to prepare a simvastatin solution with a final concentration of 0.5 mg / mL. During the period of feeding maintenance feed and high-fat feed to each group of mice, each group of mice was gavaged, specifically: the blank control group mice were gavaged with normal saline, the corn oil control group mice were gavaged with corn oil, the distilled water control group mice were gavaged with distilled water, the lycopene 1-5 groups of mice were gavaged with lycopene solutions with final concentrations of 2 mg / mL, 3 mg / mL, 5 mg / mL, 7.5 mg / mL, and 12 mg / mL, the L-carnitine 1-5 groups of mice were gavaged with L-carnitine solutions with final concentrations of 2 mg / mL, 4.5 mg / mL, 11 mg / mL, 26 mg / mL, and 60 mg / mL, and the positive control group mice were gavaged with lycopene solutions with final concentrations of 10 mg / mL, 25 mg / mL, 30 mg / mL, 50 mg / mL, and 120 mg / mL. The mice were gavaged with a simvastatin solution with a final concentration of 0.5 mg / mL, once a day, and the gavage dose was 0.1 mL / 10 g mouse body weight; so that the lycopene dosages of the mice in the lycopene 1-5 groups were 20 mg / kg, 30 mg / kg, 50 mg / kg, 75 mg / kg, and 120 mg / kg mouse body weight, the L-carnitine dosages of the mice in the L-carnitine 1-5 groups were 20 mg / kg, 45 mg / kg, 110 mg / kg, 260 mg / kg, and 600 mg / kg mouse body weight, and the simvastatin dosage of the mice in the positive control group was 5 mg / kg mouse body weight.

[0038] Experimental Example 2: The delayed effect of lycopene alone on atherosclerosis

[0039] After continuous gavage for 42 days, the mice in each group were fasted for 12 hours with unlimited drinking water. The next day, the mice were anesthetized with ether and killed. Blood samples were collected by enucleation of the eyeballs to prepare mouse serum. The levels of oxidized low-density lipoprotein (ox-LDL), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), glutathione peroxidase activity (GSH-Px), superoxide dismutase activity (SOD) and malondialdehyde (MDA) in the serum of each group of mice were determined by BS-420 automatic biochemical analyzer. The levels of total antioxidant capacity (T-AOC), tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), histamine (HIS), vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1) in the serum of each group of mice were determined by DR-200BS enzyme labeled analyzer, and the reduction rate of ox-LDL and ED were calculated. 50 The results are shown in Tables 2 to 6 and Figure 1 As shown;

[0040] The calculation formula of the reduction rate is:

[0041]

[0042] Wherein: the drug-treated groups include the positive control group and lycopene groups 1 to 5;

[0043] Lycopene for ED 50 The value was calculated based on the regression equation of lycopene to ox-LDL, and the regression equation was: y = 0.9401x - 0.9756 (R 2 =0.9462).

[0044] Table 2 Ox-LDL levels in mice in each group

[0045] Group ox-LDL (μg / L) Reduction rate (%) Blank control group <![CDATA[291.14±30.70 c ]]> —— Corn oil control group <![CDATA[422.36±26.61 a ]]> —— Positive control group <![CDATA[294.91±46.72 c ]]> 97.12 Lycopene 1 group <![CDATA[396.79±57.16 b ]]> 19.31 Lycopene 2 groups <![CDATA[368.44±57.10 bc ]]> 40.97 Lycopene 3 groups <![CDATA[326.84±57.94 bc ]]> 72.74 Lycopene 4 groups <![CDATA[316.38±51.82 c ]]> 80.72 Lycopene 5 groups <![CDATA[302.82±28.66 c ]]> 91.08

[0046] Table 3 Blood lipid indexes of mice in each group

[0047] Group TG (mmol / L) TC(mmol / L) LDL-C (mmol / L) HDL-C (mmol / L) Blank control group <![CDATA[0.84±0.22 c ]]> <![CDATA[1.74±0.35 b ]]> <![CDATA[0.88±0.19 b ]]> <![CDATA[4.47±0.93 a ]]> Corn oil control group <![CDATA[1.98±0.47 a ]]> <![CDATA[2.51±0.50 a ]]> <![CDATA[1.37±0.30 a ]]> <![CDATA[2.59±0.88 c ]]> Positive control group <![CDATA[1.13±0.38 bc ]]> <![CDATA[1.62±0.27 b ]]> <![CDATA[0.70±0.18 b ]]> <![CDATA[3.43±0.53 b ]]> Lycopene 1 group <![CDATA[1.28±0.35 b ]]> <![CDATA[1.88±0.24 b ]]> <![CDATA[0.76±0.23 b ]]> <![CDATA[2.81±0.71 bc <!-- 4 -->]]> Lycopene 2 groups <![CDATA[1.29±0.45 b ]]> <![CDATA[1.75±0.32 b ]]> <![CDATA[0.89±0.27 b ]]> <![CDATA[2.90±0.60 bc ]]> Lycopene 3 groups <![CDATA[1.24±0.39 b ]]> <![CDATA[1.77±0.36 b ]]> <![CDATA[0.83±0.26 b ]]> <![CDATA[2.95±0.58 bc ]]> Lycopene 4 groups <![CDATA[1.16±0.51 bc ]]> <![CDATA[1.69±0.29 b ]]> <![CDATA[0.71±0.18 b ]]> <![CDATA[2.91±0.70 bc ]]> Lycopene 5 groups <![CDATA[1.14±0.35 bc ]]> <![CDATA[1.57±0.28 b ]]> <![CDATA[0.73±0.26 b ]]> <![CDATA[3.32±0.67 bc ]]>

[0048] Table 4 Antioxidant capacity levels of mice in each group

[0049] Group SOD(U / mL) GSH-Px (U / mL) MDA (nmol / mL) T-AOC (U / mL) Blank control group <![CDATA[87.19±1.60 a ]]> <![CDATA[179.69±10.77 a ]]> <![CDATA[3.04±0.27 c ]]> <![CDATA[10.96±0.82 a ]]> Corn oil control group <![CDATA[56.54±2.14 d ]]> <![CDATA[127.91±16.58 c ]]> <![CDATA[4.50±0.79 a ]]> <![CDATA[5.82±0.96 d ]]> Positive control group <![CDATA[79.35±6.40 bc ]]> <![CDATA[157.18±6.75 b ]]> <![CDATA[3.44±0.14 b ]]> <![CDATA[7.80±0.49 c ]]> Lycopene 1 group <![CDATA[70.98±5.95 c ]]> <![CDATA[139.63±5.22 c ]]> <![CDATA[4.02±0.34 a ]]> <![CDATA[7.75±0.81 c ]]> Lycopene 2 groups <![CDATA[68.12±3.35 c ]]> <![CDATA[137.48±2.85 c ]]> <![CDATA[4.22±0.27 a ]]> <![CDATA[7.74±0.29 c ]]> Lycopene 3 groups <![CDATA[70.65±2.32 c ]]> <![CDATA[147.66±7.50 bc ]]> <![CDATA[3.90±0.42 ab ]]> <![CDATA[7.56±0.36 c ]]> Lycopene 4 groups <![CDATA[79.98±5.14 b ]]> <![CDATA[153.86±7.40 b ]]> <![CDATA[3.63±0.25 ab ]]> <![CDATA[8.37±0.63 bc ]]> Lycopene 5 groups <![CDATA[85.31±3.22 ab ]]> <![CDATA[166.26±10.19 ab ]]> <![CDATA[3.56±0.11 b ]]> <![CDATA[9.01±0.18 b ]]>

[0050] Table 5 Serum inflammatory factor levels of mice in each group

[0051]

[0052]

[0053] Table 6 Serum adhesion factor levels of mice in each group

[0054] Group VCAM-1 (ng / mL) ICAM-1 (pg / mL) Blank control group <![CDATA[190.84±7.99 e ]]> <![CDATA[225.83±22.98 f ]]> Corn oil control group <![CDATA[343.11±33.83 a ]]> <![CDATA[400.07±23.91 a ]]> Positive control group <![CDATA[220.41±28.17 d ]]> <![CDATA[260.05±14.90 d ]]> Lycopene 1 group <![CDATA[255.65±11.13 b ]]> <![CDATA[300.24±12.57 b ]]> Lycopene 2 groups <![CDATA[250.66±10.02 b ]]> <![CDATA[298.59±24.39 bc ]]> Lycopene 3 groups <![CDATA[247.77±10.37 bc ]]> <![CDATA[281.39±17.77 c ]]> Lycopene 4 groups <![CDATA[241.34±10.03 c ]]> <![CDATA[275.53±12.67 c ]]> Lycopene 5 groups <![CDATA[210.65±9.9 d ]]> <![CDATA[245.71±6.96 e ]]>

[0055] The results showed that lycopene can reduce ox-LDL, improve the blood lipids, serum inflammatory factors and serum adhesion factor levels of mice, and enhance the antioxidant capacity of mice, thereby delaying atherosclerosis; lycopene has an ED effect on ox-LDL. 50 The value is 33.26mg / kg.

[0056] Experimental Example 3: The delayed effect of L-carnitine alone on atherosclerosis

[0057] After continuous gavage for 42 days, the mice in each group were fasted for 12 hours with unlimited drinking water. The mice were anesthetized with ether and killed the next day. Blood samples were obtained by removing the eyeballs and mouse serum was prepared. The levels of ox-LDL, TG, TC, LDL-C, HDL-C, GSH-Px, SOD, and MDA in the serum of each group of mice were determined by using a BS-420 full-automatic biochemical analyzer. The levels of T-AOC, TNF-α, IL-6, HIS, VCAM-1, and ICAM-1 in the serum of each group of mice were determined by using a DR-200BS enzyme labeled analyzer, and the reduction rate of ox-LDL and ED were calculated. 50 The results are shown in Tables 7 to 11 and Figure 2 As shown;

[0058] The calculation formula of the reduction rate is:

[0059]

[0060] Wherein: the drug-administered groups include the positive control group and L-carnitine groups 1 to 5;

[0061] L-Carnitine for ED 50 The value was calculated based on the regression equation of L-carnitine on ox-LDL, and the regression equation was: y = 0.3173x + 0.0903 (R 2 =0.9498).

[0062] Table 7 ox-LDL levels in mice in each group

[0063] Group ox-LDL (μg / L) Reduction rate (%) Blank control group <![CDATA[291.14±30.70 c ]]> —— Distilled water control group <![CDATA[424.36±26.61 a ]]> —— Positive control group <![CDATA[294.91±46.72 c ]]> 97.12 L-Carnitine 1 set <![CDATA[363.29±57.16 b ]]> 45.51 L-Carnitine 2 groups <![CDATA[334.59±57.10b c ]]> 66.81 L-Carnitine 3 groups <![CDATA[320.83±57.94b c ]]> 77.02 L-Carnitine 4 groups <![CDATA[313.80±51.82 c ]]> 82.24 L-Carnitine 5 groups <![CDATA[294.06±28.66 c ]]> 96.89

[0064] Table 8 Blood lipid indexes of mice in each group

[0065] Group TG (mmol / L) TC(mmol / L) LDL-C (mmol / L) HDL-C (mmol / L) Blank control group <![CDATA[0.84±0.22 c ]]> <![CDATA[1.74±0.35 b ]]> <![CDATA[0.88±0.19 b ]]> <![CDATA[4.47±0.93 a ]]> Distilled water control group <![CDATA[1.98±0.47 a ]]> <![CDATA[1.98±0.32 a ]]> <![CDATA[1.10±0.32 a ]]> <![CDATA[2.23±0.45 d ]]> Positive control group <![CDATA[1.13±0.38 bc ]]> <![CDATA[1.62±0.27 b ]]> <![CDATA[0.70±0.18 b ]]> <![CDATA[3.43±0.53 b ]]> L-Carnitine 1 set <![CDATA[1.38±0.35 b ]]> <![CDATA[1.48±0.26 b ]]> <![CDATA[0.94±0.22 a ]]> <![CDATA[2.33±0.88 cd ]]> L-Carnitine 2 groups <![CDATA[1.38±0.51 b ]]> <![CDATA[1.48±0.27 b ]]> <![CDATA[0.97±0.29 a ]]> <![CDATA[2.48±0.64 bcd ]]> L-Carnitine 3 groups <![CDATA[1.23±0.21 b ]]> <![CDATA[1.57±0.23 b ]]> <![CDATA[0.94±0.29 a ]]> <![CDATA[2.53±0.38 bcd ]]> L-Carnitine 4 groups <![CDATA[1.16±0.49 bc ]]> <![CDATA[1.63±0.27 b ]]> <![CDATA[0.89±0.21 ab ]]> <![CDATA[2.74±0.56 bcd ]]> L-Carnitine 5 groups <![CDATA[1.15±0.33 bc ]]> <![CDATA[1.50±0.33 b ]]> <![CDATA[0.87±0.24 ab ]]> <![CDATA[2.46±0.53 bcd ]]>

[0066] Table 9 Antioxidant capacity level of mice in each group

[0067] Group SOD(U / mL) GSH-Px (U / mL) MDA (nmol / mL) T-AOC (U / mL) Blank control group <![CDATA[87.19±1.60 a ]]> <![CDATA[179.69±10.77 a ]]> <![CDATA[3.04±0.27 c ]]> <![CDATA[10.96±0.82 a ]]> Distilled water control group <![CDATA[60.48±3.54 c ]]> <![CDATA[126.21±5.46 d ]]> <![CDATA[4.64±0.56 a ]]> <![CDATA[6.24±0.31 d ]]> Positive control group <![CDATA[79.35±6.40 bc ]]> <![CDATA[157.18±6.75 b ]]> <![CDATA[3.44±0.14 b ]]> <![CDATA[7.80±0.49 c <!-- 6 -->]]> L-Carnitine 1 set <![CDATA[77.74±2.19 b ]]> <![CDATA[143.88±3.46 c ]]> <![CDATA[3.54±0.15 b ]]> <![CDATA[8.53±0.44 c ]]> L-Carnitine 2 groups <![CDATA[81.90±2.87 b ]]> <![CDATA[151.87±6.95 bc ]]> <![CDATA[3.65±0.24 b ]]> <![CDATA[8.70±0.68 bc ]]> L-Carnitine 3 groups <![CDATA[85.96±4.14 ab ]]> <![CDATA[151.93±7.24 bc ]]> <![CDATA[3.76±0.21 b ]]> <![CDATA[8.59±1.31 bc ]]> L-Carnitine 4 groups <![CDATA[87.61±4.66 a ]]> <![CDATA[163.94±18.70 ab ]]> <![CDATA[3.20±0.47 bc ]]> <![CDATA[9.42±0.58 b ]]> L-Carnitine 5 groups <![CDATA[91.65±4.56 a ]]> <![CDATA[183.54±6.63 a ]]> <![CDATA[2.90±0.24 c ]]> <![CDATA[10.12±0.72 ab ]]>

[0068] Table 10 Serum inflammatory factor levels of mice in each group

[0069] Group HIS (ng / mL) TNF-α(pg / mL) IL-6 (pg / mL) Blank control group <![CDATA[0.38±0.03 c ]]> <![CDATA[45.97±5.08 bc ]]> <![CDATA[126.27±5.62 b ]]> Distilled water control group <![CDATA[0.69±0.03 a ]]> <![CDATA[68.16±6.06 a ]]> <![CDATA[169.75±4.85 a ]]> Positive control group <![CDATA[0.47±0.04 b ]]> <![CDATA[54.44±2.32 b ]]> <![CDATA[142.86±6.79 b ]]> L-Carnitine 1 set <![CDATA[0.47±0.04 b ]]> <![CDATA[54.98±6.77 b ]]> <![CDATA[143.27±14.99 b ]]> L-Carnitine 2 groups <![CDATA[0.49±0.07 b ]]> <![CDATA[52.94±6.57 b ]]> <![CDATA[141.53±3.58 b ]]> L-Carnitine 3 groups <![CDATA[0.48±0.06 b ]]> <![CDATA[51.89±8.96 b ]]> <![CDATA[139.70±4.14 b ]]> L-Carnitine 4 groups <![CDATA[0.48±0.07 b ]]> <![CDATA[51.01±9.08 bc ]]> <![CDATA[136.25±3.02 b ]]> L-Carnitine 5 groups <![CDATA[0.42±0.03 bc ]]> <![CDATA[44.54±2.92 c ]]> <![CDATA[125.66±11.88 b ]]>

[0070] Table 11 Serum adhesion factor levels of mice in each group

[0071] Group VCAM-1 (ng / mL) ICAM-1 (pg / mL) Blank control group <![CDATA[190.84±7.99 c ]]> <![CDATA[225.83±22.98 c ]]> Distilled water control group <![CDATA[330.17±12.24 a ]]> <![CDATA[388.24±27.56 a ]]> Positive control group <![CDATA[220.41±28.17 b ]]> <![CDATA[260.05±14.90 b ]]> L-Carnitine 1 set <![CDATA[218.04±8.84 b ]]> <![CDATA[248.47±29.27 bc ]]> L-Carnitine 2 groups <![CDATA[225.72±12.74 b ]]> <![CDATA[255.90±20.84 bc ]]> L-Carnitine 3 groups <![CDATA[228.60±18.62 b ]]> <![CDATA[254.48±25.09 bc ]]> L-Carnitine 4 groups <![CDATA[228.41±11.18 b ]]> <![CDATA[234.49±14.27 c ]]> L-Carnitine 5 groups <![CDATA[205.66±5.63 b ]]> <![CDATA[232.63±26.93 c ]]>

[0072] The results showed that L-carnitine can reduce ox-LDL, improve the levels of blood lipids, serum inflammatory factors and serum adhesion factors in mice, and enhance the antioxidant capacity of mice, thereby delaying atherosclerosis; L-carnitine has an ED effect on ox-LDL. 50 The value is 22.43mg / kg.

[0073] Experimental Example 4: The delayed effect of lycopene combined with L-carnitine on atherosclerosis

[0074] 96 4-week-old male SPF ICR mice were selected and placed in an SPF animal room for group cage breeding according to the method described in Experimental Example 1. Then all the mice were divided into 8 groups, 12 mice in each group, namely, a blank control group, a negative control group, a positive control group, and combination groups 1 to 5, and fed and managed according to the method described in Experimental Example 1;

[0075] At 65°C, 0.5 g of sodium carboxymethyl cellulose (CMC-Na) was dissolved in 100 mL of ddH2O to obtain a 0.5% CMC-Na solution, and then lycopene and L-carnitine were added to the 0.5% CMC-Na solution to prepare combined solution 1 (lycopene with a final concentration of 0.3 mg / mL + L-carnitine with a final concentration of 0.2 mg / mL), combined solution 2 (lycopene with a final concentration of 0.6 mg / mL + L-carnitine with a final concentration of 0.4 mg / mL), and combined solution 3 (final concentration of 1.8 mg / mL) and lycopene with a final concentration of 0.6 mg / mL. / mL lycopene + final concentration of 1.2 mg / mL L-carnitine), combined solution 4 (final concentration of 4.2 mg / mL lycopene + final concentration of 2.8 mg / mL L-carnitine), combined solution 5 (final concentration of 10.8 mg / mL lycopene + final concentration of 7.2 mg / mL L-carnitine); simvastatin was dissolved in 0.5% CMC-Na solution to prepare a simvastatin solution with a final concentration of 0.5 mg / mL. During the period of feeding maintenance feed and high-fat feed to each group of mice, each group of mice was gavage-fed, specifically: the blank control group mice were gavage-fed with normal saline, the negative control group mice were gavage-fed with 0.5% CMC-Na solution, the combination groups 1 to 5 mice were gavage-fed with combination solutions 1 to 5, and the positive control group mice were gavage-fed with simvastatin solution with a final concentration of 0.5 mg / mL, once a day, and the gavage dose was 0.1 mL / 10 g of mouse body weight; so that the total dosage of lycopene and L-carnitine in the combination groups 1 to 5 mice was 5 mg / kg, 10 mg / kg, 30 mg / kg, 70 mg / kg, and 180 mg / kg of mouse body weight, and the dosage of simvastatin in the positive control group mice was 5 mg / kg of mouse body weight;

[0076] After continuous gavage for 42 days, the mice in each group were fasted for 12 hours with unlimited drinking water. The mice were anesthetized with ether and killed the next day. Blood samples were obtained by removing the eyeballs and mouse serum was prepared. The levels of ox-LDL, TG, TC, LDL-C, HDL-C, GSH-Px, SOD, and MDA in the serum of each group of mice were determined by using a BS-420 automatic biochemical analyzer. The levels of T-AOC, TNF-α, IL-6, HIS, VCAM-1, and ICAM-1 in the serum of each group of mice were determined by using a DR-200BS enzyme labeled analyzer. The reduction rate of ox-LDL and the expected ED value of lycopene combined with L-carnitine were calculated. 50 Value, actual ED 50 Value and combined action coefficient (K), the results are shown in Tables 12 to 16 and Figure 3 As shown;

[0077] The calculation formula of the reduction rate is:

[0078]

[0079] Wherein: the drug administration group includes the positive control group and combination groups 1 to 5;

[0080] Expected ED effects of lycopene combined with L-carnitine 50 The value is calculated as:

[0081]

[0082] Where: a and b are the mass ratios of lycopene and L-carnitine in the combined solution, and a+b=1; ED of lycopene 50 The value was calculated based on the regression equation of lycopene to ox-LDL, and the regression equation was: y = 0.9401x - 0.9756 (R 2 =0.9462); ED of L-carnitine 50 The value was calculated based on the regression equation of L-carnitine on ox-LDL, and the regression equation was: y = 0.3173x + 0.0903 (R 2 =0.9498);

[0083] The actual ED effect of lycopene combined with L-carnitine 50 The value was calculated based on the regression equation of lycopene combined with L-carnitine on ox-LDL, and the regression equation was: y = 0.2629x + 0.3875 (R 2 =0.9395);

[0084] The calculation formula of the combined action coefficient (K) is:

[0085] Under non-fasting gavage conditions, the Smyth method was used to determine the interaction between lycopene and L-carnitine. The criteria were: K < 0.40 for antagonism, 0.40 < K < 2.70 for additive effect, and K > 2.70 for synergistic effect.

[0086] Table 12 Ox-LDL levels in each group of mice

[0087] Group ox-LDL (μg / L) Reduction rate (%) Blank control group <![CDATA[263.85±22.94 cd ]]> —— Negative control group <![CDATA[386.25±32.46 a ]]> —— Positive control group <![CDATA[270.44±18.75 d ]]> 94.62 Combined with 1 group <![CDATA[322.78±14.63 b ]]> 51.85 Combined with 2 groups <![CDATA[300.20±10.68 c ]]> 70.30 Combined with 3 groups <![CDATA[290.11±27.39 cd ]]> 78.55 Combined with 4 groups <![CDATA[276.88±8.85 d ]]> 89.35 Combined use of 5 groups <![CDATA[269.96±30.22 d ]]> 95.01

[0088] Table 13 Blood lipid indexes of mice in each group

[0089] Group TG (mmol / L) TC(mmol / L) LDL-C (mmol / L) HDL-C (mmol / L) Blank control group <![CDATA[1.17±0.40 b ]]> <![CDATA[1.22±0.20 b ]]> <![CDATA[0.68±0.12 b ]]> <![CDATA[3.38±0.44 ab ]]> Negative control group <![CDATA[1.93±1.40 a ]]> <![CDATA[1.91±0.46 a ]]> <![CDATA[1.12±0.28 a ]]> <![CDATA[2.92±0.52 b ]]> Positive control group <![CDATA[1.55±0.61 b ]]> <![CDATA[1.31±0.15 b ]]> <![CDATA[0.62±0.15 b ]]> <![CDATA[4.67±1.12 a ]]> Combined with 1 group <![CDATA[1.70±0.22 b ]]> <![CDATA[1.77±0.49 a ]]> <![CDATA[0.70±0.08 b ]]> <![CDATA[3.07±0.24 b ]]> Combined with 2 groups <![CDATA[1.80±0.67 b ]]> <![CDATA[1.58±0.37 ab ]]> <![CDATA[0.70±0.23 b ]]> <![CDATA[3.24±0.55 b ]]> Combined with 3 groups <![CDATA[1.77±0.63 b ]]> <![CDATA[1.29±0.22 b ]]> <![CDATA[0.72±0.20 b ]]> <![CDATA[3.22±0.48 b ]]> Combined with 4 groups <![CDATA[1.81±0.57 b ]]> <![CDATA[1.31±0.23 b ]]> <![CDATA[0.81±0.32 b ]]> <![CDATA[3.12±0.35 b ]]> Combined use of 5 groups <![CDATA[1.62±0.57 b ]]> <![CDATA[1.30±0.22 b ]]> <![CDATA[0.73±0.07 b ]]> <![CDATA[3.14±0.43 b ]]>

[0090] Table 14 Antioxidant capacity level of mice in each group

[0091]

[0092]

[0093] Table 15 Serum inflammatory factor levels of mice in each group

[0094] Group HIS (ng / mL) TNF-α(pg / mL) IL-6 (pg / mL) Blank control group <![CDATA[0.66±0.08 e ]]> <![CDATA[54.78±4.94 b ]]> <![CDATA[140.04±11.25 c ]]> Negative control group <![CDATA[0.92±0.07 a ]]> <![CDATA[69.30±11.07 a ]]> <![CDATA[180.76±7.68 a ]]> Positive control group <![CDATA[0.77±0.08 cd ]]> <![CDATA[59.52±5.19 ab ]]> <![CDATA[164.06±15.98 ab ]]> Combined with 1 group <![CDATA[0.86±0.08 ab ]]> <![CDATA[67.57±3.82 a ]]> <![CDATA[171.03±4.59 a ]]> Combined with 2 groups <![CDATA[0.81±0.04 bc ]]> <![CDATA[60.80±7.52 ab ]]> <![CDATA[160.54±4.67 b ]]> Combined with 3 groups <![CDATA[0.73±0.06 d ]]> <![CDATA[59.28±6.00 ab ]]> <![CDATA[154.05±8.03 bc ]]> Combined with 4 groups <![CDATA[0.73±0.07 d ]]> <![CDATA[51.97±3.04 b ]]> <![CDATA[148.90±8.61 c ]]> Combined use of 5 groups <![CDATA[0.64±0.09 e ]]> <![CDATA[51.22±3.27 b ]]> <![CDATA[135.39±9.30 c ]]>

[0095] Table 16 Serum adhesion factor levels of mice in each group

[0096] Group VCAM-1 (ng / mL) ICAM-1 (pg / mL) Blank control group <![CDATA[209.18±15.99 d ]]> <![CDATA[242.73±26.72 c ]]> Negative control group <![CDATA[279.00±22.75 a ]]> <![CDATA[362.44±46.46 a ]]> Positive control group <![CDATA[248.19±22.62 c ]]> <![CDATA[300.80±39.36 ab ]]> Combined with 1 group <![CDATA[269.52±29.50 ab ]]> <![CDATA[354.47±25.14 a <!-- 9 -->]]> Combined with 2 groups <![CDATA[258.95±26.33 bc ]]> <![CDATA[292.51±12.80 b ]]> Combined with 3 groups <![CDATA[220.06±21.64 d ]]> <![CDATA[250.16±37.17 bc ]]> Combined with 4 groups <![CDATA[208.63±13.21 d ]]> <![CDATA[243.97±11.03 c ]]> Combined use of 5 groups <![CDATA[205.46±11.08 d ]]> <![CDATA[240.38±14.02 c ]]>

[0097] The results showed that the ED value of lycopene was calculated based on the regression equation of lycopene to ox-LDL. 50 The value is 33.26 mg / kg. The ED value of L-carnitine is calculated based on the regression equation of L-carnitine to ox-LDL. 50 The value is 22.43 mg / kg, and further calculation gives the expected ED 50 The value is 27.88 mg / kg; because in the regression equation of lycopene combined with L-carnitine on ox-LDL, R 2 The accuracy cannot reach 0.99. The actual ED is calculated according to the regression equation. 50 The value will be biased to a certain extent, so the sum of the final doses of lycopene and L-carnitine when the ox-LDL reduction rate in Table 12 is closest to 50% is taken as the actual ED 50 Value, that is, actual ED 50 The value was 5 mg / kg; the combined effect coefficient (K) was further calculated to be 5.57, indicating that under non-fasting gavage conditions, lycopene and L-carnitine showed a synergistic effect. Therefore, the combination of lycopene and L-carnitine can reduce ox-LDL, improve the blood lipids, serum inflammatory factors and serum adhesion factor levels of mice, and enhance the antioxidant capacity of mice, thereby delaying atherosclerosis.

[0098] As can be seen from the above examples, the present invention provides the use of lycopene combined with L-carnitine in the preparation of health food for preventing and / or delaying atherosclerosis. Lycopene and L-carnitine show a synergistic effect in reducing the content of ox-LDL. The combination of lycopene and L-carnitine can effectively improve the body's blood lipids, serum inflammatory factors and serum adhesion factor levels, and improve the body's antioxidant capacity, so that it can be used to prevent and / or delay the development of atherosclerosis.

[0099] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of lycopene combined with L-carnitine in the preparation of health food for preventing and / or delaying atherosclerosis.

2. The use according to claim 1, characterized in that: The mass ratio of lycopene to L-carnitine is 15-120:10-80.

3. Application of lycopene combined with L-carnitine in the preparation of health food for reducing oxidized low-density lipoprotein.

4. The use according to claim 3, characterized in that: The mass ratio of lycopene to L-carnitine is 15-120:10-80.

5. A health food, characterized in that: The health food comprises lycopene, L-carnitine and acceptable auxiliary materials.

6. The health food according to claim 5, characterized in that The mass ratio of lycopene to L-carnitine is 15-120:10-80.

7. Use of the health food according to claim 5 or 6 in the preparation of a preparation for preventing and / or delaying atherosclerosis.

8. Use of the health food according to claim 5 or 6 in the preparation of a preparation for reducing oxidized low-density lipoprotein.

Images